Download PDF
Zeitschrift für Komplementärmedizin 2014; 06(06): 40-42
DOI: 10.1055/s-0034-1396355
zkm | Wissen
Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Griffonia simplicifolia Beste Quelle für 5-Hydroxytryptophan

Josep Lluís Berdonces
Further Information

Publication History

Publication Date:
11 December 2014 (online)

    Permissions and Reprints

Keywords

Heilpflanze - Griffoniasimplicifolia - 5-Hydroxytryptamin - Angststörung - Depression
 
  • 1 Adotey A, John Nii J.. Biological characteristics of Griffonia simplicifolia and its chemical composition [J]. Subtropical Plant Science 2013; 42 ((1)) 86-90
    Google Scholar
  • 2 Bruni O et al L-5-Hydroxytryptophan treatment of sleep terrors in children. Eur J Pediatr 2004; 163 ((7)) 402-407
    Google Scholar
  • 3 Byerley WF et al 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987; 7: 127-137
    Google Scholar
  • 4 Cangiano C, Ceci F, Cascino A et al Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. J Clin Nutr 1992; 56: 863-867
    Google Scholar
  • 5 Caruso I et al Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990; 18: 201-209
    Google Scholar
  • 6 Carnevale G et al Griffonia simplicifolia negatively affects sexual behavior in female rats. Phytomedicine 2010; 17 ((12)) 987-991
    CrossrefGoogle Scholar
  • 7 Carnevale G et al Influence of Griffonia simplicifolia on male sexual behavior in rats: behavioral and neurochemical study. Phytomedicine 2011; 18 ((11)) 947-952
    CrossrefGoogle Scholar
  • 8 Carnevale G et al Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats. Phytomedicine 2011; 18 ((10)) 848-851
    Google Scholar
  • 9 Caruso I, Sarzi Puttini P, Cazzola M et al Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990; 18: 201-209
    Google Scholar
  • 10 Coleman M.. Infantile spasms associated with 5-hydroxytryptophan administration in patients with Down's syndrome. Neurology 1971; 21: 911-919
    CrossrefGoogle Scholar
  • 11 Curcio JJ et al The potential of 5-hydryxtryptophan for hot flash reduction: a hypothesis. Altern Med Rev 2005; 10 ((3)) 216-221
    Google Scholar
  • 12 Das YT et al Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 2004; 150 ((1)) 111-122
    CrossrefGoogle Scholar
  • 13 Emanuele E et al An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Phytomedicine 2010; 17 ((12)) 987-991
    CrossrefGoogle Scholar
  • 14 Freedman RR.. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas 2010; 65 ((4)) 383-385
    CrossrefGoogle Scholar
  • 15 Gambichler T et al Impact of UVA exposure on psychological aprameters and circulatin serotonin and melatonin. BMC Dermatology 2002; 2: 6
    CrossrefGoogle Scholar
  • 16 Hinz M, Stein A. Uncini T. 5-HTP efficacy and contraindications. Neuropsyciatric Disease and Treatment 2012; 8: 323-328
    Google Scholar
  • 17 Jamieson DG.. The safety of triptasns in the treatment of patients with migraine. Am J Med 2002; 112 ((2)) 135-140
    CrossrefGoogle Scholar
  • 18 Jangid P et al Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Toxicol Lett 2004; 150 ((1)) 111-122
    CrossrefGoogle Scholar
  • 19 Johnson KL, Klarskov K, Benson LM et al Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J Rheumatol 1999; 26: 2714-2717
    Google Scholar
  • 20 Juhl JH.. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. Altern Med Rev 1998; 3: 367-375
    Google Scholar
  • 21 Juhl JH.. Fibromyalgia and the serotonin pathway. Pharmacol Ther 2006; 109 ((3)) 325-338
    CrossrefGoogle Scholar
  • 22 Kahn RS, Westenberg HG.. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord 1985; 8 ((2)) 197-200
    CrossrefGoogle Scholar
  • 23 Lemaire A, Adosraku RK.. An HPLC method for the direct assay of the serotonin precursor, 5-hydroxytrophan, in seeds of Griffonia simplicifolia. Phytochemical Analysis 2002; 13 ((6)) 333-337
    CrossrefGoogle Scholar
  • 24 Lin Y et al Engineering bacterial phenylalanine 4-hydroxylase for microbial synthesis of human neurotransmitter precursor 5-hydroxytryptophan. ACS Synth Biol 2014; 3 ((7)) 497-505
    CrossrefGoogle Scholar
  • 25 Lowe SL et al L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI. Psychoneuroendocrinology 2006; 31 ((4)) 473-484
    CrossrefGoogle Scholar
  • 26 Maron E et al The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J Psychopharmacol 2004; 18 ((2)) 194-199
    CrossrefGoogle Scholar
  • 27 Michelson D et al An eosinophilia-myalgia syndrome related disorder associated with exposure to l-5-hydroxytryptophan. J Rheumatol 1994; 21 ((12)) 2261-2264
    Google Scholar
  • 28 Nakajima T, Kudo Y, Kaneko Z.. Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. Folia Psychiatr Neurol Jpn 1978; 32: 223-230
    Google Scholar
  • 29 Nicolodi M, Sicuteri F.. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol 1996; 398: 373-379
    Google Scholar
  • 30 Nolen WA et al L-5 HTP in depression resistant to reuptake inhibitors. Br J Psychiatry 1985; 147: 16-22
    CrossrefGoogle Scholar
  • 31 Poldinger W, Calanchini B, Schwarz W.. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991; 24: 53-81
    CrossrefGoogle Scholar
  • 32 Ribeiro CA.. L-5-Hydroxytryptophan in the prophilaxis of chronic tension-type headache. Headache 2000; 40 ((6)) 451-456
    CrossrefGoogle Scholar
  • 33 Robinson N, Curzon G, Theaker P.. Excretion of tryptophan metabolites in Friedreich's ataxia. J Clin Pathol 1965; 18 ((6)) 797-979
    CrossrefGoogle Scholar
  • 34 Rondanelli M et al Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. Int J Obes (Lond) 2009; 33 ((10)) 1174-1182
    CrossrefGoogle Scholar
  • 35 Rondanelli M et al Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eating and weight disorders 2012; 17 ((1)) 22-28
    Google Scholar
  • 36 Sarzi Puttini P, Caruso I.. Primary fibromyalgia syndrome and 5-hydroxy-Ltryptophan: a 90-day open study. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 2013; 199 ((7)) 601-609
    CrossrefGoogle Scholar
  • 37 Schruers K et al Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 2002; 113 ((3)) 237-243
    CrossrefGoogle Scholar
  • 38 Shaw K, Turner J, Del Mar C.. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry 2002; 36 ((4)) 488-491
    CrossrefGoogle Scholar
  • 39 Singhal AB, Caviness VS, Begleiter AF et al Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002; 58: 130-133
    CrossrefPubMedGoogle Scholar
  • 40 Smarius LJ et al Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. J Psychopharmacol 2008; 22 ((4)) 426-433
    CrossrefGoogle Scholar
  • 41 Sternberg EM et al Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. Neuropsychobiology 1988; 20 ((1)) 28-35
    CrossrefGoogle Scholar
  • 42 Sun HL et al Tramadol reduces 5-HTP induced head-twitch response in mice via the activation of mu and kappa opioid receptors. Life Sci 2003; 72 ((11)) 1221-1230
    CrossrefGoogle Scholar
  • 43 Trouillas P, Brudon F, Adeleine P.. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan: a double-blind study with quantified data processing. Arch Neurol 1988; 45: 1217-1222
    CrossrefGoogle Scholar
  • 44 Trujillo-Martín MM, Serrano-Aguilar P, Monton-Alvarez F et al Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 2009; 24 ((8)) 1111-1124
    CrossrefGoogle Scholar
  • 45 Turner EH.. 5-hydroxytryptophan plus SSRi's for interferon induced depression. Med Hypotheses 2005; 65 ((1)) 138-144
    CrossrefGoogle Scholar
  • 46 Turner EH, Loftis JM. Blackwell AD: Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Int J Neuropsychopharmacol 2009; 12 ((8)) 1067-1079
    CrossrefGoogle Scholar
  • 47 Van Praag H.. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psichiatry Res 1980; 3 ((1)) 75-83
    Google Scholar
  • 48 Van Praag H.. Chemoprophylaxis of depressions. An attempt to compare lithium with 5.HTP. Acta Psychiatr Scand 1981; 290 ((Suppl.)) 191-201
    Google Scholar
  • 49 Wang XZ et al A new β-carboline alkaloid from the seeds of Griffonia simplicifolia. Chin J Nat Med 2013; 11 ((4)) 401-405
    Google Scholar
  • 50 Weise P et al The use of 5-HTP in the treatment of Down's syndrome. Pediatrics 1974; 54 ((2)) 165-168
    Google Scholar
  • 51 Zhao X et al Chronic resveratrol treatment exerts antihyperalgesic effect and corrects co-morbid depressive like behaviors in mice with mononeuropathy: Involvement of serotonergic system. ACS Synth Biol 2014; 3 ((7)) 497-505
    CrossrefGoogle Scholar
  • 52 Zmilacher K, Battegay R, Gastpar M.. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988; 20: 28-33
    CrossrefGoogle Scholar